| For: | Zhang J, Wang X, Tian JJ, Zhu R, Duo RX, Huang YC, Shen HL. Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report. World J Clin Cases 2022; 10(4): 1286-1290 [PMID: 35211561 DOI: 10.12998/wjcc.v10.i4.1286] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i4/1286.htm |
| Number | Citing Articles |
| 1 |
Pedro N. S. L. Silva, João A. Baptista, Nuno A. S. Santos, Ricardo A. E. Castro, Manuela Ramos Silva, João Canotilho, M. Ermelinda S. Eusébio, Teresa M. R. Maria. Insights into the Solid-State Landscape of Iguratimod, a Disease-Modifying Antirheumatic Drug. Crystal Growth & Design 2026; 26(6): 2531 doi: 10.1021/acs.cgd.5c01817
|
| 2 |
KD Suryana, B Alodia. Autoimmune Hemolytic Anemia in Non-Hodgkin’s Lymphoma: Pathogenesis, Diagnosis, and Management. Nigerian Journal of Clinical Practice 2025; 28(12): 1359 doi: 10.4103/njcp.njcp_826_24
|
| 3 |
Qi Zhang, Xi-Rui Yang, Yao Deng. Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation. Cell Biochemistry and Biophysics 2024; 82(3): 2275 doi: 10.1007/s12013-024-01337-2
|
